Q-linea signs evaluation contract with reference laboratory network in the US

Q-linea AB (publ) (OMX:QLINEA) today announces that the company has signed an evaluation contract with a large network reference laboratory headquartered in the United States.

With the announcement of FDA clearance of the ASTar System and a Gram-negative panel (ASTar BC G- Consumable Kit), Q- linea has already signed a contract under the Early Evaluation Program with a large network reference laboratory and is in active conversations with several hospital systems for the same. Jim Kathrein, VP of US Commercial Operations, said: “Early interest in ASTar has been extremely positive and we are excited to demonstrate our fully automated rapid AST capabilities in the US market. We anticipate seeing continued strong results in line with our EAP data and European placements.”

Datum 2024-05-02, kl 11:02
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!